

Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells

Hsing-Chen Tsai,^{1,2,10} Huili Li,^{2,10} Leander Van Neste,^{3,10} Yi Cai,² Carine Robert,⁴ Feyruz V. Rassool,⁴ James J. Shin,^{2,5} Kirsten M. Harbom,² Robert Beaty,² Emmanouil Pappou,^{2,5} James Harris,^{2,5} Ray-Whay Chiu Yen,² Nita Ahuja,^{2,5} Malcolm V. Brock,^{2,5} Vered Stearns,^{2,6} David Feller-Kopman,⁷ Lonny B. Yarmus,⁷ Yi-Chun Lin,⁸ Alana L. Welm,⁸ Jean-Pierre Issa,⁹ Il Minn,² William Matsui,^{1,2} Yoon-Young Jang,² Saul J. Sharkis,^{1,2} Stephen B. Baylin,^{1,2,*} and Cynthia A. Zahnow^{2,6,*}

¹The Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA

²The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA

³MDxHealth PharmacoDx BVBA, Technologiepark 4, 9052 Ghent, Belgium

⁴Department of Radiation Oncology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA

⁵Department of Surgery, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA

⁶Breast Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA

⁷Bronchoscopy and Interventional Pulmonology, Johns Hopkins Hospital, Baltimore, MD 21205, USA

⁸Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA

⁹Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030 USA

¹⁰These authors contributed equally to this work

*Correspondence: sbaylin@jhmi.edu (S.B.B.), zahnow@jhmi.edu (C.A.Z.)

DOI 10.1016/j.ccr.2011.12.029

SUMMARY

Reversal of promoter DNA hypermethylation and associated gene silencing is an attractive cancer therapy approach. The DNA methylation inhibitors decitabine and azacitidine are efficacious for hematological neoplasms at lower, less toxic, doses. Experimentally, high doses induce rapid DNA damage and cytotoxicity, which do not explain the prolonged time to response observed in patients. We show that transient exposure of cultured and primary leukemic and epithelial tumor cells to clinically relevant nanomolar doses, without causing immediate cytotoxicity, produce an antitumor “memory” response, including inhibition of subpopulations of cancer stem-like cells. These effects are accompanied by sustained decreases in genomewide promoter DNA methylation, gene reexpression, and antitumor changes in key cellular regulatory pathways. Low-dose decitabine and azacitidine may have broad applicability for cancer management.

INTRODUCTION

Decitabine (DAC) and its analog azacitidine (AZA), two major DNA demethylating agents (Jones and Taylor, 1980), have recently emerged as potent therapies for the preleukemic hematological disease myelodysplastic syndrome (MDS), and for established leukemias (Blum et al., 2007; Cashen et al., 2010; Issa et al., 2004), leading to approval from the Food and Drug

Administration for patients with MDS (Kantarjian et al., 2006; Silverman et al., 2002). Remarkably, the improved clinical efficacy and safety profile have emerged only as doses of the drugs, given either alone (Issa et al., 2004; Kantarjian et al., 2006, 2007) or in combination with histone deacetylase (HDAC) inhibitors (Gore et al., 2006), were significantly reduced. Despite the clinical efficacy observed in hematological neoplasms, these lower dosing regimens have not been thoroughly tested in

Significance

The mechanisms underlying clinical efficacies of the DNA methylation inhibitors decitabine and azacitidine are unclear. Understanding how these drugs work would be a pivotal step in furthering epigenetic therapy. Clinical clues suggest that these drugs work in myelodysplastic syndrome because low doses provide antitumor effects over time rather than acutely exerting cytotoxic effects. We show that nanomolar doses of both drugs have, without acute cytotoxic effects, antitumor effects on both cultured and primary human leukemic and epithelial tumor cells, including the most tumorigenic, self-renewing, and drug-resistant cell populations. These effects are accompanied by sustained, genomewide changes in promoter DNA methylation and gene expression which affect multiple key regulatory pathways that are high-priority targets for pharmacologic anticancer strategies.

patients with common solid tumors. Past trials with high doses have been plagued by extreme toxicities that have probably confounded the ability to document true clinical responses (Abele et al., 1987; Momparler et al., 1997). Even for the successes in hematologic neoplasms, it is still under debate whether epigenetic effects of the drugs account for all, or even some, of the therapeutic response (Issa and Kantarjian, 2009). In a recently completed clinical trial for advanced lung cancer using a low-dose regimen that has efficacy in MDS, we have seen some very durable, complete, partial, and stable responses in a subset of patients who have failed multiple previous chemotherapy regimens (Juergens et al., 2011). These results emphasize the importance of deciphering the mechanisms involved with therapeutic efficacy of DAC and AZA and understanding how low, nanomolar doses of DAC and AZA are effective at inducing sustained antitumor responses.

RESULTS

Transient, Low-Dose DAC Decreases Tumorigenicity of Cultured Leukemia Cells with Minimal Acute DNA Damage, Cell Cycle Alterations, or Apoptosis

DAC and AZA were originally designed as nucleoside analogs that, at high doses, clearly produce DNA damage and cytotoxicity (Karpf et al., 2001; Pali et al., 2008). However, these effects may not be the primary mechanisms responsible for the clinical efficacy in patients with MDS or leukemia. We, thus, first sought to separate low-dose, from high-dose effects of DAC on cultured leukemia cells. We used the very low doses, indicated by pharmacokinetic studies to be in the nanomolar range for DAC (20 to 300 nM) (Cashen et al., 2008; Schrupp et al., 2006), to which tumor cells in responding patients with MDS/AML are most likely exposed in settings of clinical efficacy. Kasumi-1 cells, an acute myelogenous leukemia (AML) line with a stem-cell-like phenotype characterized by a high fraction of CD34⁺ early progenitor cells (Asou et al., 1991) (Figure S1A available online), are known to be sensitive to cytotoxic effects of high-dose DAC (Berg et al., 2007). Indeed, daily doses of 500 nM DAC for 3 days produced 50% apoptosis, which reached over 90% by 4 days after drug withdrawal (Figure S1B), while 10 nM produces little or no cell death at 3 days in Kasumi-1, KG-1, and KG-1a AML cells and in histiocytic lymphoma U-937 cells (Figures 1A and S1C). It is important to note that this lack of early cytotoxicity at 10 nM is subsequently followed, after drug withdrawal, by sustained rates of apoptosis, leveling off at ~40% for Kasumi-1 and ~25% for KG-1 leukemia cells (Figure S1D). Consistent with these observations, the 3-day 10 nM DAC exposures produce little cell cycle changes between mock and treated Kasumi-1 cells at Day 3 (Figure 1B) and 4 and 11 days after drug withdrawal (Figure S1E) or significant increases in double-strand DNA breaks in CD34⁺ and CD34[−] Kasumi-1 cells at Day 3 (Figure 1C). In contrast, 100 nM of cytarabine (Ara-C), a compound structurally similar to DAC and a standard cytotoxic chemotherapeutic agent used for AML therapy, causes distinct prolongation of S-phase (Figure 1B).

Despite the aforementioned lack of acute cytotoxic effects, the 3-day, 10 nM dose of DAC can fully (for Kasumi-1, KG-1, and KG-1a cells and partially for U-937 cells) inhibit subsequent colony formation in methylcellulose assays performed over

20 days in drugfree media (Figures 1A and S1C). Similarly, 100 nM DAC produces no initial apoptosis in chronic myelogenous leukemia, K-562 cells, but sharply reduces subsequent colony formation (Figure S1C). Acute promyelocytic leukemia NB4 cells are sensitive to both early apoptosis and diminishing of proliferation at 10 nM DAC (Figure S1C).

It is important to note that these anticloning effects for sensitive cells such as Kasumi-1 are sustained and wane only slowly after drug removal. First, the 10 nM dose of DAC blunts clonogenic potential of the cells in repeated methylcellulose colony-forming assays performed without subsequent drug exposure over 28 days (Figure S1F). Second, the transient 3-day exposure of 10 nM also inhibits, in serial methylcellulose replating assays, colony formation for Kasumi-1 (Figure 1D) and KG-1 (Figure S1G) cells and markedly decreases this ability for U-937 and K-562 cells (Figure S1G). In contrast, 10 or 100 nM doses of Ara-C produce much less inhibition of colony growth (Figure 1A). Finally, 10 nM DAC for 3 days also markedly blunts cloning of Kasumi-1 and KG-1 cells in a 5-week, drugfree, feeder layer assay that supports long-term culture-initiating cells (LTC-IC) (Figure 1E). Ara-C, again, fails to reduce LTC-IC (Figure 1E), which is consistent with the known poor capability of this drug to target such leukemic cell populations (Guzman et al., 2001).

The ultimate test of tumor initiation for leukemia and solid tumor cells (Lapidot et al., 1994; Al-Hajj et al., 2003; Li et al., 2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Schatton et al., 2008; Singh et al., 2004) is engraftment capability and tumor growth of the most tumorigenic or more "stem-like" cells in mice (Jordan et al., 2006). Kasumi-1 has a high percentage of stem-like CD34⁺ cells. Only purified CD34⁺, and not CD34[−], Kasumi cells are tumorigenic in mice (Figure 1F). Of note, our transient, low-dose treatment with DAC inhibits colony formation of both CD34⁺ and CD34[−] Kasumi-1 cells (Figure 1G). Most strikingly, a 3-day treatment of Kasumi-1 cells to 10 nM DAC markedly delays, without any drug treatment of recipient animals, detectable engraftment of Kasumi-1 cells in the peripheral blood and the bone marrow of NOD/Shi-*scid*/IL-2R γ^{null} mice (Figures 1H and 1I) and decreases the percentage of CD34⁺ leukemic stem/progenitor cells that do appear in bone marrow (Figure 1J). Thus, a 10 nM transient DAC exposure markedly inhibits subsequent leukemia-initiating CD34⁺ in vivo.

Low-Dose DAC, without Acute Cytotoxicity, Blunts Clonogenicity of Primary Leukemia Cells but Not Primary Normal Bone Marrow Cells

Low-dose DAC can produce many of the same effects observed earlier on primary AML cells without the toxic effects on primary bone marrow cells. Thus, a 3-day transient 10 nM dose of DAC markedly blunts the ability of five of six primary samples from patients with newly diagnosed AML to subsequently clone in methylcellulose (Figure 2A) without causing early cell apoptosis or change in cell cycle (Figures 2B and 2C). This same 10 nM dose of DAC fails to blunt the ability of a normal bone marrow sample to generate progenitor colonies for multiple marrow lineages and did not cause significant apoptosis (Figures 2D and 2E). All of the aforementioned results are consistent with clinical results for MDS/AML, wherein delayed, robust antitumor responses can be produced while the normal bone marrow parameters are restored.




Figure 1. Low-Dose DAC Treatment Diminishes Self-Renewing and Leukemia-Initiating Capacities in Cultured Leukemia Cells

(A) Apoptosis and methylcellulose colony-forming assays of Kasumi-1 cells after 72 hr daily treatment with DAC or cytarabine (Ara-C). * $p < 0.05$ compared to mock by analysis of variance (ANOVA) and Dunnett's multiple comparison test.

(B) Cell cycle analysis of Kasumi-1 after DAC or Ara-C daily treatment for 72 hr. * $p < 0.05$ by ANOVA and Bonferroni posttests.

Transient Low Doses of DAC and AZA Inhibit Cultured Solid Tumor Stem-like Cells and Diminish Tumorigenicity

We next determined doses of DAC/AZA that were acutely nontoxic to cultured breast cancer cells but that might affect their tumorigenic properties. We found that transient 3-day exposure of MCF7 cells to 100 nM DAC at Day 3 of drug treatment or 4 days after drug withdrawal (day 7), or an equivalent dose of 500 nM AZA at 7 days after drug withdrawal (day 10), produced little apoptosis (Figure S2A). Similarly, 3 days of exposure to 100 nM DAC or 500 nM AZA led to minimal cell cycle changes over time (Figure S2B). Significant decreases were observed for MCF7 cells in anchorage-independent growth in soft agar, a classic *in vitro* transformation assay, for both 100 nM DAC and 500 nM AZA (Figure S2C). Similarly, 3-day treatments with 10 nM DAC (Figure S2D), 100 nM DAC (Figure 3B), and 500 nM AZA (Figure 3C), followed by subcutaneous injection into untreated nonobese diabetic (NOD)/SCID mice (Figure 3A), significantly reduced the size of MCF7 xenografts. This diminished tumorigenicity persisted in serially transplanted secondary xenografts (Figures 3A and 3B). An even stronger decrease was produced in tumor growth for T-47D breast cancer cells. Growth was also suppressed for HCT116 colon and H2170 lung cancer lines (Figure 3C). Moreover, for clinical relevance, we tested several short cycles and therapeutic doses of AZA in mice bearing established xenografts of MDA-MB-231, MCF7, and T-47D breast cancer cells. In MDA-MB-231 and T-47D xenografts, the lowest dose of drug led to the largest reduction in tumor size, whereas in MCF7 xenografts, all doses were comparable (Figure 3D). There were, again, no changes in proliferative capacity of cells in the treated MCF7 tumors (Figure S2E).

Transient Low Doses of AZA Inhibit Primary Breast Cancer Stem-like and Self-Renewing Cells

We further investigated the effects of transient, low-dose AZA treatment on the self-renewal potential of primary cancer cells isolated from the pleural effusions of four patients with metastatic breast cancer of the luminal type. These cells were treated for 3 days with 500 nM AZA, followed by drug withdrawal and culture in suspension as tumor spheres and serially passaged to test for self-renewal capacity and stem-like cell activity (Figure 4A) (McDermott and Wicha, 2010; Korkaya et al., 2009; Charafe-Jauffret et al., 2009; Dontu et al., 2003; Ginestier et al., 2007;

Liu et al., 2006). There was dramatic inhibition of primary sphere formation and an inhibitory effect that persisted through two subsequent serial passages (Figure 4B), while spheres from mock-treated cells showed a trend toward enrichment from passage two to passage three (see patients #103, #PE1, and #105; Figure 4B). Thus, 3 days of exposure to low-dose AZA reduces the self-renewal capacity of primary breast cancer cells consistent with our observation that AZA treatment decreases a self-renewing population in breast cancer cell lines. Aldehyde dehydrogenase (ALDH1) and CD44⁺/CD24^{lo} have emerged as markers for cancer stem-like cells in breast and are predictive for metastasis and poor prognosis (Al-Hajj et al., 2003; Ginestier et al., 2007). We find, in agreement with others, that the MCF7 breast cancer line has ~0.5% ALDH1⁺ cells (Charafe-Jauffret et al., 2009) and T47Ds contain ~5% CD44⁺/CD24^{lo} (data not shown). A 3-day treatment with 500 nM AZA and 10 nM DAC significantly reduced CD44⁺/ALDH1⁺ cells for up to 17 days after drug withdrawal (Figure 4C), with no changes observed in the larger CD44⁺/ALDH1⁻ cell population (data not shown). Similar results were observed for 100 nM DAC (data not shown). For T-47D cells, a similar 3-day treatment with 500 nM AZA reduced the CD44⁺/CD24^{lo} population for up to 11 days after drug withdrawal (Figure 4C). Likewise, 3 days of 500 nM AZA decreased the CD44⁺/CD24^{lo} population in mammospheres from patient #105 (Figure 4C).

Last, we tested the effects of low-dose AZA on primary tumor tissue from breast cancer patients. Therapeutic administration of AZA (0.5 mg/kg) significantly inhibited the growth of three preestablished, patient-derived tumors, engrafted orthotopically into immunodeficient mice (Figure 4D) (DeRose et al., 2011).

Low-Dose DAC Inhibits Gene Promoter DNA Methylation and Causes Re-Expression of Hypermethylated Genes

The ability of transient low doses of DAC to sustain long-term antitumor effects is associated, at least temporally, with the retained ability of this drug to target DNA methylation processes and alter gene expression, in each of the cell types under study. DAC and AZA, after their incorporation into DNA, are known to bind to and block the catalytic site of DNA methyltransferases (DNMTs). This covalent binding effectively traps DNMTs as adducts to DNA (Ferguson et al., 1997; Gabbara and Bhagwat, 1995; Santi et al., 1984). Additionally, DAC and AZA can trigger proteosomal degradation of the maintenance DNMT, DNMT1

(C) γ H2AX foci formation in CD34⁺ and CD34⁻ Kasumi-1 cells after 72 hr DAC treatment. For each treatment, cells containing more than 15 foci are counted and calculated as fold change relative to that of mock treatment. ns, not statistically significant by ANOVA and Bonferroni posttests.

(D) Serial methylcellulose replating assays of Kasumi-1 after 72 hr daily treatment of DAC or Ara-C. Equal numbers of viable cells were plated for each plating.

**p* < 0.01 compared to mock by ANOVA and Bonferroni posttests.

(E) Long-term culture-initiating cell assay of Kasumi-1 and KG-1 AML cells after 72 hr daily treatment of DAC or Ara-C. **p* < 0.05 compared to mock by Mann-Whitney test.

(F) Engraftment assay in NOD/Shi-scid/IL-2R γ^{null} mice of CD34⁺ versus CD34⁻ Kasumi-1 cells. Human CD45⁺ cells were analyzed in the peripheral blood (PB) and bone marrow (BM) of transplant mice 4 to 5 months posttransplantation. No engraftment was observed in any mice receiving CD34⁻ cells.

(G) Methylcellulose colony-forming assay of CD34⁺ and CD34⁻ Kasumi-1 cells after 72 hr daily treatment with 10 nM DAC. **p* < 0.001, compared to mock, by ANOVA with Bonferroni posttests.

(H and I) Engraftment assay in NOD/Shi-scid/IL-2R γ^{null} mice of Kasumi-1 cells pretreated daily with 10 nM DAC for 72 hr. Percentage of human leukemia cells in peripheral blood (H) and in bone marrow (I) is shown. *p* values were calculated by Mann-Whitney test.

(J) Percentage of CD34⁺ and CD34⁻ Kasumi-1 AML cells after daily treatment of 10 nM DAC for 72 hr *in vitro* and after engraftment in mouse bone marrow.

**p* < 0.05 by Mann-Whitney test. All error bars represent standard errors.

See also Figure S1.




Figure 2. DAC at Non-Acutely Cytotoxic Doses Blunts Clonogenicity of Primary Human Leukemia Cells but Not Normal Bone Marrow Cells
 (A) Methycellulose colony-forming assay of bone marrow mononuclear cells from six patients with newly diagnosed AML after 72 hr daily DAC treatment and 4-day recovery period in vitro. Images and quantifications of colonies are shown in upper and lower panels, respectively. * $p < 0.05$ compared to mock by ANOVA

(Ghoshal et al., 2005). Three days of 10 nM DAC leads to early depletion of DNMT1 protein in Kasumi-1, KG-1, and KG-1a leukemia cells, and 100 nM gives a similar effect in three different breast cancer lines (Figure 5A). Despite these similar effects on early depletion of DNMT1 in all tested cell lines, the duration of the effect does not correlate with the later phenotypic consequences of drug treatment described earlier. Thus, while DNMT1 protein levels quickly recover in most of the lines, DNMT1 depletion lasts for at least 25 days after drug withdrawal in Kasumi-1 cells, although the phenotypic responses of these cells are similar to those of KG-1 cells (Figure 5A). Thus, transient or sustained inhibition of DNMT1 protein expression by 3 days of DAC treatment accompanies prolonged, subsequent, antitumor effects.

In keeping with the early depletion of DNMT1 protein levels, low-dose DAC causes demethylation and reexpression of DNA hypermethylated and epigenetically silenced genes. A 3-day exposure to 10 nM DAC produces, in both CD34⁺ and CD34[−] Kasumi-1 cells, significant demethylation of the completely methylated and silenced tumor suppressors *CDKN2B* and *CDH1* (Figures 5B and 5C). One particularly important finding with respect to the cellular phenotypes observed involves the expression of some initially silenced genes. In the treatment schema used wherein cells are not acutely killed, we see in both Kasumi-1 and KG-1a cells increased transcription long after drug withdrawal. This is exemplified by *CDKN2B*, for which the peak expression is reached at Day 14, or 11 days after cessation of drug administration (Figure 5D).

It is important to note that these methylation effects are seen across the genome in analyses of DNA methylation by using the Methylation 27 BeadChip for cultured cells and the more probe-dense HumanMethylation450 BeadChip 450K for the treated 1107 and 1307 primary leukemia cells (Figure 2A). DAC (10 nM) for 72 hr causes a distinct decrease in methylation for essentially all probes and genes with high initial levels of DNA methylation in Kasumi-1 cells (Figures 6A and 6B), many of which are also heavily methylated in DNA from primary AML samples (Figure S3A). The decreases can be seen in promoter regions of both CpG island- and non-CpG island-containing genes (Figure 6C). This dose similarly reduces global methylation of highly methylated genes in KG-1 and KG-1a cells, as does 100 nM in breast cancer MCF7 cells (Figure S3B). Treatment of a primary leukemia sample (PL6347) with 10 nM DAC, after proliferation stimulation with cytokines, similarly causes decreases in gene promoter region DNA methylation (Figures 6B and S3B). Virtually identical results have been seen for primary, treated leukemia

samples 1107 and 1307 using the 450K platform (data not shown).

The aforementioned genomic promoter demethylation induced by low-dose DAC is accompanied by widespread increases in gene expression (scatter plot for Kasumi-1 cells; Figures S3C and S3D). In fact, up to 50% of genes whose expression increase after transient low dose exposure remain increased for up to 14 days (Figure S3E). Among such genes are those having decreases in their cancer-specific promoter hypermethylation after drug treatment, such as *CDKN2B* in Kasumi-1 (Figure 5C) and KG-1a AML cells (Figure S5), *CDKN2A* in KG-1a cells, and six hypermethylated genes (Figure 6D) studied by Lubbert and colleagues (Flotho et al., 2009), or our lab, in Kasumi-1 cells, *DAPK1*, *CDKN1C* (also known as *p57KIP2*), *HOXA9*, *HGF*, *DLK1*, and *RAB13*. All these eight genes have increased expression by Day 3 of low-dose decitabine treatment, and seven have sustained increases at least 11 days after treatment cessation (Figure 6D).

Transient Low Doses of DAC and AZA Induce Sustained Alterations in Major Cancer Cell Signaling Pathways

Cancer is driven by alterations of gene function in key cellular pathways (Hanahan and Weinberg, 2011). We find, using Metacore analyses of gene expression, changes in many key antitumor pathways (Figures 7A, 7B, S4A, and S4B; Tables S1 and S2).

Changes in gene expression, which would block cell proliferation and decrease tumor self-renewing populations, were often correlated with increases in expression of more than one cyclin-dependent kinase inhibitors (*CDKN2B*, *CDKN2A*, *CDKN1A*) and were associated with CpG island DNA demethylation for *CDKN2B* in leukemia cells (Figures 7A and 7B). The upregulation of *p14ARF*, *CDKN2A*, *CDKN1A*, and other key hypermethylated pathway genes, such as *SLIT2* and *ROBO3*, were validated in cultured leukemia cells (Figure 8A). The FOXM1-polo-kinase (PLK)-Aurora kinase pathway would be predicted to be downregulated secondary to the aforementioned gene increases (Koo et al., 2012). We observed this in both cultured (KG-1a AML) and primary leukemia cells (#1107 in Figure 2A) and in primary breast cancer mammosphere samples (#103 and #104 in Figure 4A; Figure 7B). In each case, *CDKN1A* expression was increased and could be linked to DNA demethylation in a DNA methylated region (Figure 7C) just upstream from a nonhypermethylated CpG island. This pathway, required for cells to enter and perform cell division and to maintain DNA damage-triggered cell cycle check points, is increased in tumors with poor prognosis

and Dunnett's multiple comparison test. Scale bar, 500 μ m. #1307 and #29, AML with FLT3-ITD mutation; #1107, AML FAB M2; #30, AML with mutated NPM1; #9, secondary AML; #20, AML FAB M5.

(B) Annexin V apoptosis assay of one representative AML patient sample (#1307) after 72 hr daily DAC treatment in vitro. Bone marrow mononuclear cells were harvested for analysis at the end of 72 hr drug treatment (Day 3) and 6 days after drug removal (Day 9). ns, not statistically significant by ANOVA with Bonferroni posttests.

(C) Cell cycle analysis on one representative AML patient sample (#1307) was performed 4 days after drug removal (Day 7) with DNA content measured using propidium iodide staining. ns, not statistically significant by ANOVA with Bonferroni posttests.

(D) Methylcellulose colony-forming assays of human normal bone marrow mononuclear cells (BM #1 and #2) after 72 hr daily DAC treatment in vitro. CFU-E, colony-forming unit erythroid; BFU-E, burst-forming unit erythroid; CFU-GM, colony-forming unit granulocyte, macrophage; CFU-GEMM, colony-forming unit granulocyte, erythrocyte, macrophage, megakaryocyte. ns, not statistically significant by ANOVA with Bonferroni posttests.

(E) Annexin V apoptosis assay in one representative bone marrow sample (BM #1) after DAC treatment in vitro. Cells were double-stained with Annexin-V and propidium iodide, and percentage of cells relative to total cells is shown in each quadrant. All error bars represent standard errors.




Figure 3. DAC and AZA at Noncytotoxic Doses Decrease Tumorigenicity in Mouse Tumor Xenografts

(A) Schematic outline of xenograft tumorigenicity assay in NOD/SCID mice for MCF7 (breast), T-47D (breast), HCT116 (colon), and H2170 (lung) cancer cells after 7- to 14-day recovery period after 100 nM DAC or 500 nM AZA daily treatment for 72 hr.

(B) Primary and secondary xenograft assays of MCF7 cells pretreated with 100 nM DAC. Equal numbers of viable cells were injected in each transplantation. p value is calculated by ANOVA. n = 6 for each treatment group.

and has been linked to progenitor cell renewal and increased cellular invasion, motility, and metastatic potential (Koo et al., 2012; Raychaudhuri and Park, 2011). Loss of G2M cell cycle checkpoint control and the downregulation of *FOXM1*, aurora kinases, polo kinases, *CHK1*, *CHK2*, and *MYT1* represent proteins currently targeted by the pharmaceutical industry to induce cancer cell apoptosis and/or sensitization to cytotoxic drugs (Carrassa and Damia, 2011; Merry et al., 2010). In bone marrow samples from two leukemia patients who responded to DAC treatment in a clinical trial, sustained DNA demethylation and increased expression of *CDKN2B* is detected at early time points before reduction of the leukemic tumor clone and coincident with decreases in *FOXM1* RNA (Figures 8B and 8C).

We also saw decreased *AKT* mRNA, and downregulation of key regulatory genes, *TWIST*, *SLUG*, and *SNAIL* (Hanahan and Weinberg, 2011), which activate epithelial to mesenchymal transition (EMT) (Figure 7A). EMT has been closely linked to stem-like populations in breast cancer and we observe down regulation of EMT genes in treated, self-renewing primary mammosphere cells from patients 103 and 104 (Figure 4A; Table S2). Correlative studies in the laboratory reveal decreased phosphorylation of *AKT* in cultured MCF7 breast cancer cells (Figure 8D).

In the self-renewing, primary mammosphere cultures, we saw changes predictive of diminished cell motility, invasiveness, induction of angiogenesis, and metastatic potential including decreased mRNA expression for genes encoding the integrins, metalloproteinases, and the key cytoskeletal remodeling protein ezrin (Figure S4A; Table S2). These genes can be overexpressed in breast cancer, and their downregulation is matched by upregulation of mRNA for genes that suppress these cell processes, such as the often hypermethylated tissue inhibitors of metalloproteinases (*TIMPs*), thrombospondin, and the complement receptor, *C5AR* (Table S2). It is important to note that breast cancer sample PE1, after 3-day treatment with 500 nM AZA, appears less invasive and forms a more compact sphere in matrigel (Figure 8E).

Finally, both cultured and primary cells harbored gene expression changes that predict cell maturation events. Kasumi-1 AML and primary AML sample 1107 had decreased expression of the G-CSF receptor and of the *c-myc* gene and increased expression, with decreased DNA methylation of the transcription region, for the transcription factor *RARA* (Figures 8A and S5). Coordinately, myeloid commitment at the progenitor cell level was indicated by DNA demethylation and increased expression of the normally methylated early myeloid lineage genes, *LYZ* and *ELANE* (Figures S4B and S5; and Table S1); increases in *CD13* (Figure S4B), a marker of cells with bipotential maturation to erythroid and granulocyte cells (Chen et al., 2007); and mature granulocyte formation (Levy et al., 1990) by increased *p47-phox*, *p67-phox*, and *Gp91-phox* (Figure S4B; Table S1). All of these changes were observed both in DAC-treated total AML cells and tumorigenic CD34⁺ cells from Kasumi-1 AML (Fig-

ure S4B). Also, increased TGF-beta signaling was observed, and this is known to promote maturation and inhibition of leukemic progenitor cell renewal (Figure 7A) (Lewis et al., 2001; Watabe and Miyazono, 2009). Concomitantly, there is decreased canonical WNT pathway signaling associated with reduced methylation; increased expression of *WIF1* (Figures 7A and S5), a Wnt antagonist gene; and downstream decrease in expression of *c-myc* (Figure 7A), a canonical target for Wnt pathway activation (He et al., 1998). Of note, we validated myelocyte differentiation by flow cytometric analysis of a surface marker for mature granulocyte, CD11b, in a treated primary AML sample 29 (Figure 8F). Sustained increase of cytokeratin 18 (CK18) in DAC- or AZA-treated MCF7 cells, as well as in tumor xenografts from mice treated for 6 weeks with AZA (Figure 8G), was also observed. CK18 expression reflects maturation of breast luminal cells, and loss of CK18 is associated with poor prognosis in breast cancer patients (Woelfle et al., 2004).

DISCUSSION

Our present studies indicate that treatment of cancer cells with clinically relevant low doses of DAC and AZA can exert sustained changes in gene expression and critical signaling pathways involved in tumorigenesis without inducing immediate cytotoxic effects such as DNA damage, apoptosis, and cell cycle arrest. Our preclinical use of transient 3-day exposure to such doses *ex vivo* produces a “memory” type of antitumor response in mice bearing transplanted tumor xenografts, which may resemble the prolonged time to response seen in patients with hematologic neoplasms (Kantarjian et al., 2006; Oki et al., 2008; Silverman et al., 2002). In patient tumors and mammospheres, the antitumor response occurred more quickly and appeared to be more sensitive to AZA than that observed for cancer-cell-line-generated tumors. This may be explained by the fact that the human tumors were exposed to a longer, more sustained treatment and that primary tissues may be initially more sensitive to AZA. All of these aforementioned dynamics after transient drug exposure are accompanied by genomewide, prolonged gene promoter DNA demethylation and sustained increases in gene expression, some of which occur for key tumor suppressor genes in leukemia and breast cancer cells.

There are several reasons to suggest that at least one key mechanism underlying the antitumor responses we demonstrate may involve a resetting of abnormal epigenetic states in treated cancer cells. First, we have achieved a sustained change in the pattern of gene expression without changing primary DNA sequence. Second, as defined for an epigenetic change, these sustained changes persist for significant periods of time after a transient, subsequently withdrawn, signal (i.e., in this case, drug treatment). Third, altered expression patterns are accompanied by antitumor effects. It is important to note that we probably have brought out these aspects of DAC and

(C) Primary xenograft assays of MCF7, T-47D, HCT116, and H2170 cells pretreated with 500 nM AZA. p value is calculated by ANOVA. n = 10 for each treatment group.

(D) AZA treatment of mice with pre-established MDA-MD-231, MCF7, or T-47D breast tumors. Tumor volumes are measured at the end of each cycle. *Statistical significance determined by two-way ANOVA (p < 0.05). All error bars represent standard errors.

See also Figure S2.




Figure 4. Low-Dose DAC and AZA Decrease Self-Renewal and Tumorigenesis in Primary Breast Cancer Tissue from Patients

(A) Tumor sphere assays of primary breast cancer cells from pleural effusions after 500 nM AZA daily treatment for 3 days *in vitro*. Images and quantifications of tumor spheres are shown in upper and lower panels, respectively. Scale bars, 500 μ m.

AZA treatment by using doses that do not acutely kill cells and, thus, allow the sustained alterations in both gene expression patterns and appearance of, to our knowledge, a new phenotype to emerge. Of note, these changes include antitumor events in multiple key pathways, such as apoptosis, increased lineage commitment, downregulation of cell cycling, and others, which continue well after drug removal. Reprogramming might, then, be considered a very desirable type of targeted therapy that can blunt multiple tumor signaling pathways simultaneously.

Perhaps one of the most striking effects observed in our study concerns the fact that nanomolar doses of both DAC and AZA appear to target, in both cell lines and primary samples of leukemia and breast cancers, self-renewing and/or tumorigenic cell subpopulations. This involves stem-like CD34⁺ cells in leukemia and CD44⁺/ALDH1⁺, CD44⁺/CD24^{LO}, and mammosphere-forming cells in breast cancer. These findings should be considered in the context that one of the most important problems in cancer therapy is the failure of most therapies to target the subpopulations that are most responsible for sustained tumor cell renewal (Jordan et al., 2006). Our findings suggest that the often prolonged time course to response in patients with myelodysplasia or frank AML might involve a progressive exhaustion of cell populations. This hypothesis is supported by recent reports that depleting DNMT1, by non-pharmacologic means, in normal mouse hematopoietic and human epithelial cells blocks self-renewal and proper cell maturation, leading to cellular depletion of progenitor cells (Bröske et al., 2009; Sen et al., 2010; Trowbridge et al., 2009). DAC and AZA do deplete DNMT1 in leukemia and breast cancer cells for variable time periods after transient exposure (Figure 4A). However, the mechanisms underlying our pharmacologically induced responses are certainly more complex since both DAC and AZA inhibit the catalytic sites of DNMT3a and DNMT3b as well. Also, all the DNMTs assuredly participate in complex protein interactions where they may exert scaffolding functions with effects on other chromatin regulatory features (Robertson et al., 2000; Rountree et al., 2000). They also, experimentally, have effects for repressing gene expression that may not require their directly catalyzing DNA methylation (Bachman et al., 2001). This complexity may actually give DAC and AZA an important advantage in treating cancer cells where they may target all of these functions and their role in governing the epigenetic aberrancies present in cancer. If so, the activities we find for low nanomolar doses may be very important in rendering these drugs as gold standards for the development of agents to target DNA methylation and other epigenetic abnormalities as an anti-cancer strategy to inhibit the most tumorigenic subpopulations of cells.

In summary, our findings have much relevance for strategies to use DAC and AZA more widely for the management of cancer.

These drugs are already making an impact for patients with hematological malignancies. Our findings now suggest ways and biomarkers that might be used to predict and/or monitor clinical efficacy. The similar “memory” type of responses we find for primary and cultured breast cancer cells, and the key pathway changes seen, indicate that the treatment of many cancers may be considered and with doses that will be not only efficacious but also minimally toxic to patients. Such possibilities are emerging in our recently completed trial, sponsored by Lung Cancer SPORE and Stand Up to Cancer (SU2C), for patients with advanced non-small-cell lung carcinoma (Juergens et al., 2011). SU2C trials in breast cancer have now begun that might be well informed by the preclinical studies we now report. Moreover, it is especially appealing to consider that DAC and AZA might sensitize tumor cells to other drugs, as is suggested by Juergens et al. (2011), that target the oncogenic pathways we have shown to be altered and allow use of reduced, less toxic, doses for these other agents.

EXPERIMENTAL PROCEDURES

Methylcellulose Colony-Forming Assay and Serial Replating Assay

After a 3-day drug treatment, equal numbers of viable cells were plated in triplicate on to MethoCult H4434 Classic or MethoCult H4435 Enriched (StemCell Technologies, Vancouver, British Columbia, Canada). Colonies containing more than 40 cells were quantified at 10–16 days under an inverted microscope. For serial replating assays, equal numbers of viable cells from the first plating were plated in triplicate in the second plating. Colonies were again scored after 16–21 days.

Long-Term Culture-Initiating Cell Assay

After a 3-day drug treatment, equal numbers of viable leukemia cells (trypan blue negative) were plated on to a feeder layer of irradiated M2-10B4 mouse fibroblasts (StemCell Technologies) and maintained via biweekly one-half medium changes in MyeloCult H5100 according to the manufacturer's instructions (StemCell Technologies). After 5 weeks, cells were harvested and plated on to MethoCult H4435 Enriched (StemCell Technologies), and colonies were counted after 14–18 days.

Immunophenotypic Staining and Fluorescence-Activated Cell Sorting

Human anti-CD34-FITC, anti-CD34-APC, anti-CD38-PE, anti-CD33-APC, anti-CD15-FITC, anti-CD14-PE, anti-CD11b-APC, anti-CD45-perCP, anti-CD45-APC, anti-CD44-APC, anti-CD24-PE, and corresponding isotype controls were obtained from BD Biosciences, San Jose, CA, USA. The ALDEFLUOR Assay kit (StemCell Technologies) was used to identify cells expressing high levels of aldehyde dehydrogenase (ALDH). Cells were stained according to the manufacturer's instructions and analyzed on a FACSCalibur Flow Cytometer (BD Biosciences) using BD CellQuest Pro v.5.2 (BD Biosciences). For sorting, CD34 cells with upper or lower 10% fluorescent intensity were collected (FACSVantage Cell sorter or BD FACSAria II cell sorter; BD Biosciences).

Leukemia Engraftment Assay

Cells were tail vein injected into sublethally irradiated (3.0 cG) female NOD/Shi-scid/IL-2Rγ^{null} mice 6–8 weeks of age. Peripheral blood was sampled every

(B) Serial passages of tumor spheres formed by primary breast cancer cells after the initial 3-day AZA treatment. Equal numbers of viable cells were plated in each passage. The data show a sustained decrease in self-renewal capacity of tumor spheres.

(C) Flow cytometric analyses of CD44⁺/ALDH⁺ in MCF7 cells, CD44⁺/CD24^{LO} cells in T-47D, and primary breast cancer sample #105 after AZA or DAC daily treatment for 3 days and subsequent drug removal. Statistical significance was determined via two-way ANOVA.

(D) In vivo AZA treatment of immunodeficient mice bearing orthotopically transplanted primary breast cancer cells from patients. AZA (0.5 mg/kg) was administered intraperitoneally 5 days/week. All error bars represent standard errors.




Figure 5. Low-Dose DAC Inhibits Gene Promoter DNA Methylation and Causes Sustained Re-expression of Hypermethylated Genes

(A) Western blot of DNMT1 expression levels in human leukemia cells (Kasumi-1, KG-1a, and KG-1) and breast cancer cells (MCF7, MDA-MB-231, and T-47D) after 72 hr daily treatment of 10 nM (leukemia) or 100 nM (breast cancer) DAC.

(B) Methylation-specific PCR (MSP) analyses of gene promoter DNA methylation in unsorted, CD34⁺, and CD34⁻ Kasumi-1 cells before DAC treatment. U, unmethylated sequence amplifications; M, methylated sequence amplifications; IVD, in vitro methylated DNA; NL, normal lymphocyte DNA.

(C) MSP analyses of *CDKN2B* and *CDH1* promoters in CD34⁺ and CD34⁻ Kasumi-1 cells at 24, 48, and 72 hr of DAC treatment.

(D) Quantitative real-time PCR analyses of *CDKN2B* gene expression over time in Kasumi-1 and KG-1a cells after 72 hr daily treatment of 10 nM DAC. Expression levels are adjusted to *GAPDH* for each sample and graphed as fold changes relative to mock. All error bars represent standard errors.




Figure 6. Genome-wide Methylation and Expression Analyses after Short-Term Exposure to Low-Dose DAC

(A) Histogram of Infinium results for Kasumi-1 methylation profiles after daily DAC or Ara-C treatment for 72 hr. y axis, frequency of probes; x axis, CpG probe beta scores (lowest to highest = increasing DNA methylation).


(B) Heat map composed of minimal variation beta probes located at $-1,000$ to $+200$ bp surrounding transcription start site ($\sim 5,500$ genes). Blue and orange colors on the left denote non-CpG and CpG island promoters, respectively. PL6347, PL1, PL2, PL4, PL5 are the primary leukemia samples. PL6347+DAC: primary leukemia after 72 hr 10 nM DAC treatment. mock and mock (rep), untreated Kasumi-1 cells and its replicate. Ara-C, Kasumi-1 cells treated with 100 nM Ara-C daily for 72 hr. TSA, Kasumi-1 cells treated with 300 nM trichostatin A for 9 hr. DAC (day 3, day 3 rep, day 7, day 14, day 21, day 28), Kasumi-1 cells harvested at various time points after 72 hr daily treatment of 10 nM DAC.

(C) Box plots showing beta value changes over time in CpG island (upper panel) and non-CpG island gene promoters (lower panel) in Kasumi-1 cells after 72 hr daily treatment of 10 nM DAC. Ara-C, 100 nM AraC treatment for 72 hr. TSA, 300 nM TSA treatment for 9 hr.


(D) Left panel shows beta value changes after 72 hr, 10 nM DAC treatment for six genes in Kasumi-1 with basal beta values ≥ 0.5 . Right panel shows corresponding Agilent expression changes normalized to Day 0. Gray horizontal lines: bottom to top, no change (\log_2 scale = 0), 1.4-fold (0.5), and 2.0-fold (1.0).

See also Figure S3.

A



B



C




Figure 7. Metacore Pathway Analyses of Agilent Expression Changes after DAC or AZA Treatment

(A) Key pathways and/or master genes, shown here for studies in cultured cells. Genes in black type indicate genes with expression changes not directly linked to promoter DNA methylation. Genes in red type indicate genes with basal promoter hypermethylation, drug-induced demethylation, and corresponding increases in expression. Superscript 1, 2, and 3 by genes or pathways indicate, respectively, Kasumi-1 AML cells, KG-1a AML cells, and MCF7 breast cancer cells with expression changes concordant in the indicated cell line.

4 weeks, and bone marrow was harvested from each mouse at 13–15 weeks. Engraftment was determined by immunophenotypic staining using human anti-CD45-perCP and anti-CD34-APC (BD Biosciences).

Solid Tumor Xenograft Tumorigenicity Assay

MCF7, T-47D, HCT116, and H2170 cells were pretreated with 100 nM decitabine, 500 nM azacytidine, or PBS (Mock) for 72 hr, followed by another 4–7 days in culture without drug. Harvested cells were injected (1×10^6) subcutaneously into both flanks of 4- to 6-week-old NOD/SCID mice. Female mice receiving MCF7 cells were implanted with estrogen pellets (0.72 mg/60 days; Innovative Research of America, Sarasota, FL, USA). Secondary xenografts were generated by collagenase dissociation of primary MCF7 tumors at 8 weeks, followed by reinjection of 1×10^6 viable cells into mice.

Therapeutic Administration of AZA to NOD-SCID Mice with Pre-established Tumors

Mice with preestablished MDA-MB-231, MCF7, or T-47D xenotumors (0.3–0.5 cm) received subcutaneous daily saline (mock) or azacitidine injections (2, 1, 0.5, 0.25, or 0.125 mg/kg) for 8 days over a 14-day period per cycle, as outlined in Figure 2D. Five mice (10 tumors) were used per treatment group.

For xenograft experiments using cell lines, tumors were measured weekly and volume was calculated as $0.5 \times (L \times W^2)(\text{mm}^3)$. Protocols for all animal experiments conducted at Johns Hopkins were approved by the John Hopkins University Animal Care and Use Committee and guidelines were strictly enforced. Experiments using human tumor xenografts and conducted at the Huntsman Cancer Institute were reviewed and approved by the University of Utah Institutional Animal Care and Use Committee.

In Vitro Culture of Primary Human Leukemia and Normal Bone Marrow Cells

Frozen bone marrow mononuclear cells from patients with freshly diagnosed acute myelogenous leukemia (#1107 and #1307) or healthy controls (BM #1 and #2) were thawed and cultured in Poietics HPGM (Lonza, Inc., Walkersville, MD, USA) supplemented with multiple cytokines described in the Supplemental Experimental Procedures. Provision of all primary bone marrow and leukemia samples was through protocols approved by the institutional review boards (IRBs) at the University of Maryland School of Medicine, The Johns Hopkins Medical Institutions, and The University of Texas M.D. Anderson Cancer Center.

Tumor Sphere Assays of Primary Breast Cancer Cells

Malignant pleural effusions were collected under an IRB-approved protocol at the Johns Hopkins Medical Institutions from women with metastatic breast cancer undergoing thoracentesis as part of clinical care and who provided a written consent for use of leftover fluid. The fluid was enriched for malignant epithelial cells via centrifugation and lysing of red blood cells. Tumorspheres were maintained on ultralow adherent plates (Corning Inc., Lowell, MA, USA) in MammoCult (StemCell Technologies) or MCF10A media. (See the Supplemental Experimental Procedures for details.) Tumorspheres were treated daily for 3 days with 500 nM AZA and were cultured 4 more days after drug withdrawal. Primary spheres were counted and digested with 0.05% trypsin (Invitrogen, Carlsbad, CA, USA) into single cells. Equal numbers of live cells were plated in ultralow attachment plates to generate the second spheres. Again, spheres were counted on Day 7 and digested to generate the third spheres.

Global Gene Expression and Methylation Analysis

Gene expression profiles were analyzed, for queried cells, with Agilent Human 4 × 44K expression arrays (Agilent Technologies, Santa Clara, CA, USA). Global methylation analysis was performed with the Illumina Infinium Human Methylation27 BeadChip or HumanMethylation450 BeadChip (Illumina, Inc., San Diego, CA, USA). Data were processed using R and BioConductor.

Metacore Pathway Analysis

All probes from the Agilent Human 4 × 44K expression arrays with a change of at least .5 (\log_2 scale) up or down at any of the investigated time points were selected for further analysis and used as input for the Metacore (GeneGo, Inc.) pathway analysis. Details are described in the Supplemental Experimental Procedures.

ACCESSION NUMBERS

All microarray data are deposited in the GEO database under accession number GSE20945.

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures, two tables, and Supplemental Experimental Procedures and can be found with this article online at doi:10.1016/j.ccr.2011.12.029.

ACKNOWLEDGMENTS

We thank Drs. Peter A. Jones and Charles M. Rudin and multiple other members of our SU2C team, charged with bringing epigenetic therapy to the clinical management of all types of cancer, for critically reviewing the paper and for making helpful suggestions throughout. We thank Dr. Ying Ye for providing part of the primary leukemia samples used in this study. We thank Ada J. Tam from the flow cytometry core facility and Wayne Yu from the microarray core facility at Sidney Kimmel Comprehensive Cancer Center for their technical assistance. We also thank Stacie Jeter and Shannon Slater for regulatory support and recruitment of patients to the clinical study.

This work was, in part, supported by Grant CA 116160 from the National Institutes of Health, the Lung Spore in Cancer NCI Grant CA058184, and by funds from the Entertainment Industry Foundation and Lee Jeans, SU2C, the Samuel Waxman Cancer Research Foundation, the Irving A. Hansen Memorial Foundation (C.A.Z.), the Safeway Foundation (C.A.Z.), the Department of Defense Breast Cancer Research Program (BC075015 to A.L.W.), and The Huntsman Cancer Foundation (A.L.W.). H.-C.T. is a David Workman Student Scholar of the Samuel Waxman Cancer Research Foundation, and C.A.Z. is an Evelyn Grollman Glick Scholar. The clinical study was supported by the Cindy Rosencrans Fund for Triple Negative Breast Cancer Research.

H.-C.T., C.A.Z., and S.B.B. designed the study, analyzed data, and wrote the article. L.V.N. performed bioinformatic analyses. C.A.Z. designed and conducted animal studies for solid tumors. Y.-Y.J. and S.J.S. helped design animal studies for leukemia. H.-C.T., H.L., J.J.S., K.H., E.P., J.H., and I.M. conducted solid tumor xenograft mouse experiments. H.-C.T., R.-W.C.Y. and H.L. performed all in vitro assays for leukemia and breast cancer cells. Y.C. and H.L. performed western assays. C.R. and F.V.R. conducted DNA damage assays and provided primary leukemia samples. H.-C.T. and R.-W.C.Y. performed methylation and gene expression studies. W.M. provided primary leukemia samples and helped with study design. V.S. was responsible for all

(B) An example of pathway diagram summarizes gene changes for cultured and primary AML and breast cancer samples after transient in vitro treatment of DAC or AZA. Events depicted illustrate key expression increases in cyclin-dependent kinase inhibitors (*CDKN2B*, *CDKN2A*, *CDKN1A*), which are known to trigger decreased activity of the *FOXO1* pathway and all of the decreases shown earlier for *FOXO1* itself and the other key participants for cycle entry and progression and including the oncogene *Skp2*.

(C) Analyses of DNA methylation by HumanMethylation450 BeadChip for multiple CpG sites in the *CDKN1A* proximal promoter region. Note that a normally heavily methylated (two normal bone marrow samples) region 5' to the unmethylated CpG island (large green bar), surrounding an alternate gene start site (small arrow), is distinctly demethylated after 10 nM DAC treatment in #1107 primary AML cells, which show all of the pathway changes but not to the same degree as in #1307 AML cells, where *CDKN1A* expression is not increased and the pathway changes seen are not present.

See also Figure S4 and Tables S1 and S2




Figure 8. Validation of Changes in Multiple Signaling Pathways after DAC or AZA Treatment

(A) Quantitative real-time PCR verification for selected genes with expression changes indicated by the Metacore analyses. * $p < 0.05$ determined by ANOVA and Bonferroni posttests.

(B) Quantitative real-time PCR analyses of gene expression changes in bone marrow samples taken from patients #1 (partial responder with AML) and #2 (complete responder with CMML) at pretreatment and various time points during or after administration of DAC (20 mg/m² IV over 1 hr daily \times 5 days every 4 weeks). mRNA levels of two genes, *CDKN2B* and *FOXM1*, at each time point were plotted relative to the baseline level after adjusted by a control housekeeping gene, *GAPDH*.

regulatory aspects of patient recruitment to the clinical study that provided primary effusion samples, and D.F.-K. and L.B.Y. assisted with patient recruitment and conducted thoracentesis. A.L.W. and Y.-C.L. provided and treated primary human xenografts with AZA. J.-P.I. provided DNA and RNA samples from DAC-treated leukemia patients. S.B.B., C.A.Z., L.V.N., and H.-C.T. contributed to pathway analyses.

Received: November 3, 2010

Revised: June 20, 2011

Accepted: December 30, 2011

Published: March 19, 2012

REFERENCES

- Abele, R., Clavel, M., Dodion, P., Brunsch, U., Gundersen, S., Smyth, J., Renard, J., van Glabbeke, M., and Pinedo, H.M. (1987). The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. *Eur. J. Cancer Clin. Oncol.* 23, 1921–1924.
- Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. (2003). Prospective identification of tumorigenic breast cancer cells. *Proc. Natl. Acad. Sci. USA* 100, 3983–3988.
- Asou, H., Tashiro, S., Hamamoto, K., Otsuji, A., Kita, K., and Kamada, N. (1991). Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. *Blood* 77, 2031–2036.
- Bachman, K.E., Rountree, M.R., and Baylin, S.B. (2001). Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. *J. Biol. Chem.* 276, 32282–32287.
- Berg, T., Guo, Y., Abdelkarim, M., Fliegauf, M., and Lübbert, M. (2007). Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. *Leuk. Res.* 31, 497–506.
- Blum, W., Klisovic, R.B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., et al. (2007). Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. *J. Clin. Oncol.* 25, 3884–3891.
- Bröske, A.M., Vockentanz, L., Kharazi, S., Huska, M.R., Mancini, E., Scheller, M., Kuhl, C., Enns, A., Prinz, M., Jaenisch, R., et al. (2009). DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. *Nat. Genet.* 41, 1207–1215.
- Carrassa, L., and Damia, G. (2011). Unleashing Chk1 in cancer therapy. *Cell Cycle* 10, 2121–2128.
- Cashen, A.F., Shah, A.K., Todt, L., Fisher, N., and DiPersio, J. (2008). Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). *Cancer Chemother. Pharmacol.* 61, 759–766.
- Cashen, A.F., Schiller, G.J., O'Donnell, M.R., and Dipersio, J.F. (2010). Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. *J. Clin. Oncol.* 28, 556–561.
- Charafe-Jauffret, E., Ginestier, C., Iovino, F., Wicinski, J., Cervera, N., Finetti, P., Hur, M.H., Diebel, M.E., Monville, F., Dutcher, J., et al. (2009). Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. *Cancer Res.* 69, 1302–1313.
- Chen, L., Gao, Z., Zhu, J., and Rodgers, G.P. (2007). Identification of CD13+CD36+ cells as a common progenitor for erythroid and myeloid lineages in human bone marrow. *Exp. Hematol.* 35, 1047–1055.
- DeRose, Y.S., Wang, G., Lin, Y.-C., Bernard, P.S., Buys, S.S., Ebbert, M.T.W., Factor, R., Matsen, C., Milash, B.A., Nelson, E., et al. (2011). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. *Nat. Med.* 17, 1514–1520.
- Dontu, G., Abdallah, W.M., Foley, J.M., Jackson, K.W., Clarke, M.F., Kawamura, M.J., and Wicha, M.S. (2003). In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. *Genes Dev.* 17, 1253–1270.
- Ferguson, A.T., Vertino, P.M., Spitzner, J.R., Baylin, S.B., Muller, M.T., and Davidson, N.E. (1997). Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2'-deoxycytidine-induced cytotoxicity in human breast cancer cells. *J. Biol. Chem.* 272, 32260–32266.
- Flotho, C., Claus, R., Batz, C., Schneider, M., Sandrock, I., Ihde, S., Plass, C., Niemeyer, C.M., and Lübbert, M. (2009). The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. *Leukemia* 23, 1019–1028.
- Gabbara, S., and Bhagwat, A.S. (1995). The mechanism of inhibition of DNA (cytosine-5)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. *Biochem. J.* 307, 87–92.
- Ghoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T., and Jacob, S.T. (2005). 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. *Mol. Cell. Biol.* 25, 4727–4741.
- Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C.G., Liu, S., et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* 1, 555–567.
- Gore, S.D., Baylin, S., Sugar, E., Carraway, H., Miller, C.B., Carducci, M., Grever, M., Galm, O., Dausers, T., Karp, J.E., et al. (2006). Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. *Cancer Res.* 66, 6361–6369.
- Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M., and Jordan, C.T. (2001). Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. *Blood* 98, 2301–2307.
- Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144, 646–674.
- He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., Morin, P.J., Vogelstein, B., and Kinzler, K.W. (1998). Identification of c-MYC as a target of the APC pathway. *Science* 281, 1509–1512.
- Issa, J.P., and Kantarjian, H.M. (2009). Targeting DNA methylation. *Clin. Cancer Res.* 15, 3938–3946.
- Issa, J.P., Garcia-Manero, G., Giles, F.J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C.S., Cortes, J., and Kantarjian, H.M. (2004). Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. *Blood* 103, 1635–1640.
- Jones, P.A., and Taylor, S.M. (1980). Cellular differentiation, cytidine analogs and DNA methylation. *Cell* 20, 85–93.
- Jordan, C.T., Guzman, M.L., and Noble, M. (2006). Cancer stem cells. *N. Engl. J. Med.* 355, 1253–1261.

(C) Methylation-specific PCR analysis of *CDKN2B* promoter on the bone marrow sample of patient #1 at pretreatment, Day 4, Day 17, and Day 30 during the treatment cycle. U, unmethylated sequence amplifications; M, methylated sequence amplifications.

(D) Western blot analysis of total and phosphorylated AKT in MCF7 breast cancer cells after 100 nM DAC (upper panel) and 500 nM AZA (lower panel) treatment.

(E) Three-dimensional assay in Matrigel of a primary breast cancer sample PE1 after 3-day treatment with 500 nM AZA and subsequent drug removal. Scale bars, 100 μ m.

(F) Flow cytometric analysis of surface CD11b expression in primary AML sample #29 at 14 days after 72 hr 10 nM DAC treatment.

(G) Immunofluorescence staining of cytokeratin 18 in cultured MCF7 cells 4 days after 72 hr 100 nM DAC or 500 nM AZA daily treatment (upper panel) and in MCF7 xenograft tumors removed from mock- and AZA-treated mice (lower panel) at 6 weeks. Scale bars, 100 μ m. All error bars represent standard errors.

See also Figure S5.

- Juergens, R.A., Wrangle, J., Vendetti, F.P., Murphy, S.C., Zhao, M., Coleman, B., Seebree, R., Rodgers, K., Hooker, C.M., Franco, N., et al. (2011). Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. *Cancer Discovery* 1, 598–607.
- Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006). Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. *Cancer* 106, 1794–1803.
- Kantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., et al. (2007). Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. *Blood* 109, 52–57.
- Karpf, A.R., Moore, B.C., Ririe, T.O., and Jones, D.A. (2001). Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. *Mol. Pharmacol.* 59, 751–757.
- Koo, C.Y., Muir, K.W., and Lam, E.W. (2012). FOXM1: From cancer initiation to progression and treatment. *Biochim Biophys Acta* 1819, 28–37.
- Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S.G., and Wicha, M.S. (2009). Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. *PLoS Biol.* 7, e1000121.
- Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M.A., and Dick, J.E. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 367, 645–648.
- Levy, R., Rotrosen, D., Nagauker, O., Leto, T.L., and Malech, H.L. (1990). Induction of the respiratory burst in HL-60 cells. Correlation of function and protein expression. *J. Immunol.* 145, 2595–2601.
- Lewis, J.L., Chinswangwatanakul, W., Zheng, B., Marley, S.B., Nguyen, D.X., Cross, N.C., Banerji, L., Glassford, J., Thomas, N.S., Goldman, J.M., et al. (2001). The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells. *Blood* 97, 2604–2610.
- Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., Wicha, M., Clarke, M.F., and Simeone, D.M. (2007). Identification of pancreatic cancer stem cells. *Cancer Res.* 67, 1030–1037.
- Liu, S., Dontu, G., Mantle, I.D., Patel, S., Ahn, N.S., Jackson, K.W., Suri, P., and Wicha, M.S. (2006). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. *Cancer Res.* 66, 6063–6071.
- McDermott, S.P., and Wicha, M.S. (2010). Targeting breast cancer stem cells. *Mol. Oncol.* 4, 404–419.
- Merry, C., Fu, K., Wang, J., Yeh, I.J., and Zhang, Y. (2010). Targeting the checkpoint kinase Chk1 in cancer therapy. *Cell Cycle* 9, 279–283.
- Momparler, R.L., Bouffard, D.Y., Momparler, L.F., Dionne, J., Belanger, K., and Ayoub, J. (1997). Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. *Anticancer Drugs* 8, 358–368.
- O'Brien, C.A., Pollett, A., Gallinger, S., and Dick, J.E. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 445, 106–110.
- Oki, Y., Jelinek, J., Shen, L., Kantarjian, H.M., and Issa, J.P. (2008). Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. *Blood* 111, 2382–2384.
- Palii, S.S., Van Emburgh, B.O., Sankpal, U.T., Brown, K.D., and Robertson, K.D. (2008). DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. *Mol. Cell. Biol.* 28, 752–771.
- Raychaudhuri, P., and Park, H.J. (2011). FoxM1: a master regulator of tumor metastasis. *Cancer Res.* 71, 4329–4333.
- Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., and De Maria, R. (2007). Identification and expansion of human colon-cancer-initiating cells. *Nature* 445, 111–115.
- Robertson, K.D., Ait-Si-Ali, S., Yokochi, T., Wade, P.A., Jones, P.L., and Wolffe, A.P. (2000). DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. *Nat. Genet.* 25, 338–342.
- Rountree, M.R., Bachman, K.E., and Baylin, S.B. (2000). DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. *Nat. Genet.* 25, 269–277.
- Santi, D.V., Norment, A., and Garrett, C.E. (1984). Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. *Proc. Natl. Acad. Sci. USA* 81, 6993–6997.
- Schatton, T., Murphy, G.F., Frank, N.Y., Yamaura, K., Waaga-Gasser, A.M., Gasser, M., Zhan, Q., Jordan, S., Duncan, L.M., Weishaupt, C., et al. (2008). Identification of cells initiating human melanomas. *Nature* 451, 345–349.
- Schrump, D.S., Fischette, M.R., Nguyen, D.M., Zhao, M., Li, X., Kunst, T.F., Hancox, A., Hong, J.A., Chen, G.A., Pishchik, V., et al. (2006). Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. *Clin. Cancer Res.* 12, 5777–5785.
- Sen, G.L., Reuter, J.A., Webster, D.E., Zhu, L., and Khavari, P.A. (2010). DNMT1 maintains progenitor function in self-renewing somatic tissue. *Nature* 463, 563–567.
- Silverman, L.R., Demakos, E.P., Peterson, B.L., Kornblith, A.B., Holland, J.C., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., DeCastro, C.M., et al. (2002). Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. *J. Clin. Oncol.* 20, 2429–2440.
- Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., and Dirks, P.B. (2004). Identification of human brain tumour initiating cells. *Nature* 429, 396–401.
- Trowbridge, J.J., Snow, J.W., Kim, J., and Orkin, S.H. (2009). DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. *Cell Stem Cell* 5, 442–449.
- Watabe, T., and Miyazono, K. (2009). Roles of TGF-beta family signaling in stem cell renewal and differentiation. *Cell Res.* 19, 103–115.
- Woelfle, U., Sauter, G., Santjer, S., Brakenhoff, R., and Pantel, K. (2004). Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. *Clin. Cancer Res.* 10, 2670–2674.